The Journal of Practical Medicine >
Improvement and exploration of potassium⁃competitive acid blockers dual therapy for the eradication of Helicobacter pylori
Received date: 2024-04-10
Online published: 2024-10-22
Helicobacter pylori infection is an important causative factor in a variety of gastrointestinal diseases， such as atrophic gastritis， peptic ulcer disease， and gastric cancer. Timely eradication treatment is conducive to maintaining the health of patients. With the increase of drug resistance in Helicobacter pylori， dual therapy with proton pump inhibitors combined with high?dose amoxicillin has gradually gained attention. Potassium?competitive acid blockers are new types of antacids that have a faster onset of action and a longer lasting acid suppression effect than traditional proton pump inhibitors， making it more suitable for dual therapy. In recent years， scholars have carried out a lot of exploration， improvement and verification of potassium?competitive acid blockers dual therapy， and this article reviews its research progress.
Weiwei CHEN , Ruolin PENG , Yi QU , Zhenyu. ZHANG . Improvement and exploration of potassium⁃competitive acid blockers dual therapy for the eradication of Helicobacter pylori[J]. The Journal of Practical Medicine, 2024 , 40(19) : 2806 -2812 . DOI: 10.3969/j.issn.1006-5725.2024.19.024
| 1 | HOOI J K Y， LAI W Y， NG W K， et al. Global Prevalence of Helicobacter pylori Infection： Systematic Review and Meta-Analysis ［J］. Gastroenterology， 2017， 153（2）： 420-429. doi:10.1053/j.gastro.2017.04.022 |
| 2 | REN S， CAI P， LIU Y， et al. Prevalence of Helicobacter pylori infection in China： A systematic review and meta-analysis ［J］. J Gastroenterol Hepatol， 2022， 37（3）： 464-470. doi:10.1111/jgh.15751 |
| 3 | USUI Y， TANIYAMA Y， ENDO M， et al. Helicobacter pylori， Homologous-Recombination Genes， and Gastric Cancer ［J］. N Engl J Med， 2023， 388（13）： 1181-1190. |
| 4 | SUGIMOTO M， HIRA D， MURATA M， et al. Effect of Antibiotic Susceptibility and CYP3A4/5 and CYP2C19 Genotype on the Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy ［J］. Antibiotics （Basel）， 2020， 9（10）： 645. |
| 5 | KAGAMI T， SAHARA S， ICHIKAWA H， et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole， with reference to CYP2C19 genotype ［J］. Aliment Pharmacol Ther， 2016， 43（10）： 1048-1059. |
| 6 | HOSHINO S， KAWAMI N， TAKENOUCHI N， et al. Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis ［J］. Digestion， 2017， 95（2）： 156-161. |
| 7 | TSUJIMAE M， YAMASHITA H， HASHIMURA H， et al. A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori ［J］. Digestion， 2016， 94（4）： 240-246. |
| 8 | TANABE H， YOSHINO K， ANDO K， et al. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication ［J］. Ann Clin Microbiol Antimicrob， 2018， 17（1）： 29. |
| 9 | OZAKI H， HARADA S， TAKEUCHI T， et al. Vonoprazan， a Novel Potassium-Competitive Acid Blocker， Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice： A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy ［J］. Digestion， 2018， 97（3）： 212-218. |
| 10 | GOTODA T， KUSANO C， SUZUKI S， et al. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naive cohort of junior high school students in Japan ［J］. J Gastroenterol， 2020， 55（10）： 969-976. doi:10.1007/s00535-020-01709-4 |
| 11 | FURUTA T， YAMADE M， KAGAMI T， et al. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan， Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori ［J］. Digestion， 2020， 101（6）： 743-751. doi:10.1159/000502287 |
| 12 | SUE S， KONDO M， SATO T， et al. Vonoprazan and high-dose amoxicillin dual therapy for Helicobacter pylori first-line eradication： A single-arm， interventional study ［J］. JGH Open， 2023， 7（1）： 55-60. |
| 13 | HU Y， XU X， OUYANG Y B， et al. Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China： A prospective， randomized clinical pilot study ［J］. Helicobacter， 2022， 27（4）： e12896. |
| 14 | LIN Y， XU H， YUN J， et al. The efficacy of vonoprazan combined with different dose amoxicillin on eradication of Helicobacter pylori： an open， multicenter， randomized clinical study ［J］. Ann Transl Med， 2022， 10（18）： 987. |
| 15 | SAKURAI Y， NISHIMURA A， KENNEDY G， et al. Safety， Tolerability， Pharmacokinetics， and Pharmacodynamics of Single Rising TAK-438 （Vonoprazan） Doses in Healthy Male Japanese/non-Japanese Subjects ［J］. Clin Transl Gastroenterol， 2015， 6（6）： e94. |
| 16 | YANG F， YU B， QIN L， et al. A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori ［J］. Medicine （Baltimore）， 2023， 102（41）： e35610. doi:10.1097/md.0000000000035610 |
| 17 | QIAN H S， LI W J， DANG Y N， et al. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy ［J］. Am J Gastroenterol， 2023， 118（4）： 627-634. |
| 18 | YAN T L， WANG J H， HE X J， et al. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication： A Multicenter Randomized Clinical Trial ［J］. Am J Gastroenterol， 2024，119（4）：655-661. |
| 19 | HAN Y Y， ZHOU L， HU Y L， et al. Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection： a prospective， multi-center， randomized controlled study ［J］. J Gastroenterol， 2023， 58（12）： 1167-1177. |
| 20 | PENG X， YAO J Y， MA Y Q， et al. Efficacy and Safety of Vonoprazan-Amoxicillin Dual Regimen With Varying Dose and Duration for Helicobacter pylori Eradication： A Multicenter， Prospective， Randomized Study ［J］. Clin Gastroenterol Hepatol， 2024，22（6）：1210-1216. |
| 21 | HU Y， XU X， LIU X S， et al. Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection： A prospective， open-labeled， randomized non-inferiority clinical study ［J］. Front Immunol， 2022， 13： 1049908. |
| 22 | PENG X， CHEN H W， WAN Y， et al. Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy： a multicenter， prospective， randomized， parallel-controlled study ［J］. Clin Exp Med， 2023， 23（7）： 4011-4019. |
| 23 | SU N Y， SHI Q， MEI H， et al. Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection： A propensity score matching analysis ［J］. Helicobacter， 2023， 28（5）： e13003. |
| 24 | YU J， LV Y M， YANG P， et al. Safety and effectiveness of vonoprazan-based rescue therapy for Helicobacter pylori infection ［J］. World J Gastroenterol， 2023， 29（20）： 3133-3144. |
| 25 | GAO W， TENG G， WANG C， et al. Eradication rate and safety of a "simplified rescue therapy"： 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication： A real-world， retrospective clinical study in China ［J］. Helicobacter， 2022， 27（5）： e12918. |
| 26 | ZUBERI B F， ALI F S， RASHEED T， et al. Comparison of Vonoprazan and Amoxicillin Dual Therapy with Standard Triple Therapy with Proton Pump Inhibitor for Helicobacter Pylori eradication： A Randomized Control Trial ［J］. Pak J Med Sci， 2022， 38（4Part-II）： 965-969. doi:10.12669/pjms.38.4.5436 |
| 27 | GAO W， XU Y， LIU J， et al. A real-world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy or failed in previous amoxicillin-containing therapies ［J］. Helicobacter， 2023， 28（2）： e12947. |
| 28 | GAO W， LIU J， WANG X， et al. Simplified Helicobacter pylori therapy for patients with penicillin allergy： a randomised controlled trial of vonoprazan-tetracycline dual therapy ［J］. Gut， 2024，73（9）：1414-1420. |
| 29 | SHAO Q Q， YU X C， YU M， et al. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China： A single-center， prospective， open-label， randomized-controlled trial ［J］. Helicobacter， 2022， 27（2）： e12876. doi:10.1111/hel.12876 |
| 30 | CHEY W D， MEGRAUD F， LAINE L， et al. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe： Randomized Clinical Trial ［J］. Gastroenterology， 2022， 163（3）： 608-619. |
| 31 | RATANA-AMORNPIN S， SANGLUTONG L， EIAMSITRAKOON T， et al. Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan ［J］. Helicobacter， 2023， 28（6）： e13019. |
| 32 | JENKINS H， SAKURAI Y， NISHIMURA A， et al. Randomised clinical trial： safety， tolerability， pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 （vonoprazan）， a novel potassium-competitive acid blocker， in healthy male subjects ［J］. Aliment Pharmacol Ther， 2015， 41（7）： 636-648. doi:10.1111/apt.13121 |
| 33 | PENG X， CHENG L， YOU Y， et al. Oral microbiota in human systematic diseases ［J］. Int J Oral Sci， 2022， 14（1）： 14. |
| 34 | JI Y， LIANG X， LU H. Analysis of by high-throughput sequencing： Helicobacter pylori infection and salivary microbiome ［J］. BMC Oral Health， 2020， 20（1）： 84. doi:10.1186/s12903-020-01070-1 |
| 35 | SUZUKI N， BEPPU R， YONEDA M， et al. Effects of eradication of Helicobacter pylori on oral malodor and the oral environment： a single-center observational study ［J］. BMC Res Notes， 2020， 13（1）： 406. |
| 36 | HU Y， XU X， OUYANG Y B， et al. Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication ［J］. Helicobacter， 2022， 27（5）： e12923. |
| 37 | PENG R， ZHANG Z， QU Y， et al. The impact of Helicobacter pylori eradication with vonoprazan-amoxicillin dual therapy combined with probiotics on oral microbiota： a randomized double-blind placebo-controlled trial ［J］. Front Microbiol， 2023， 14： 1273709. |
| 38 | TRIFAN A， GIRLEANU I， COJOCARIU C， et al. Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication ［J］. World J Gastroenterol， 2013， 19（42）： 7476-7479. |
| 39 | CHIBA M， TSUJI T， TAKAHASHI K， et al. Onset of Ulcerative Colitis after Helicobacter pylori Eradication Therapy： A Case Report ［J］. Perm J， 2016， 20（2）： e115-e118. |
| 40 | MURAD H A. Does Helicobacter pylori eradication therapy trigger or protect against Crohn's disease？ ［J］. Acta Gastroenterol Belg， 2016， 79（3）： 349-354. |
| 41 | LIOU J M， CHEN C C， CHANG C M， et al. Long-term changes of gut microbiota， antibiotic resistance， and metabolic parameters after Helicobacter pylori eradication： a multicentre， open-label， randomised trial ［J］. Lancet Infect Dis， 2019， 19（10）： 1109-1120. |
| 42 | HORII T， SUZUKI S， TAKANO C， et al. Lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication ［J］. J Gastroenterol Hepatol， 2021， 36（12）： 3314-3321. doi:10.1111/jgh.15572 |
| 43 | HU Y， XU X， OUYANG Y B， et al. Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication ［J］. Front Cell Infect Microbiol， 2022， 12： 881968. |
| 44 | LEE K J， SON B K， KIM G H， et al. Randomised phase 3 trial： tegoprazan， a novel potassium-competitive acid blocker， vs. esomeprazole in patients with erosive oesophagitis ［J］. Aliment Pharmacol Ther， 2019， 49（7）： 864-872. |
| 45 | CHO Y K， CHOI M G， CHOI S C， et al. Randomised clinical trial： tegoprazan， a novel potassium-competitive acid blocker， or lansoprazole in the treatment of gastric ulcer ［J］. Aliment Pharmacol Ther， 2020， 52（5）： 789-797. |
| 46 | JUNG Y S， KIM S， KIM H Y， et al. Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori： A Real-World Evidence Study ［J］. Gut Liver， 2023，17（5）：711-721. doi:10.5009/gnl220218 |
| 47 | KIM J S， KO W， CHUNG J W， et al. Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection： A randomized， double-blind， active-controlled study ［J］. Helicobacter， 2023， 28（3）： e12977. |
| 48 | LIU H N， WANG R， CAO Y， et al. Comparison of the efficacy between the dual therapy of tegoprazan and the quadruple therapy of tegoprazan： A randomized， controlled， multicenter study ［J］. Clin Transl Gastroenterol， 2024. doi：10.14309/ctg.0000000000000699 |
| 49 | KONG Q， MIRZA I A， ZHANG X， et al. Fourteen-Day Tegoprazan-Amoxicillin Dual Therapy as the First-Line Treatment of Helicobacter pylori Infection （SHARE2301）： A Multicenter， Noninferiority， Randomized Clinical Trial ［J］. Helicobacter， 2024， 29（3）： e13098. |
| 50 | JIANG Y， ZHANG R， FANG Y， et al. P-CAB versus PPI in the eradication of Helicobacter pylori： a systematic review and network meta-analysis ［J］. Therap Adv Gastroenterol， 2024， 17： 1-20. doi:10.1177/17562848241241223 |
/
| 〈 |
|
〉 |